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ABSTRACT
Renal cell carcinoma (RCC) and neuroendocrine 
tumors (NET) are uncommon malignancies, 
highly resistant to chemotherapy, that have 
emerged as attractive platforms for evaluating 
novel targeted regimens. Everolimus is an oral 
rapamycin derivative within the mammalian 
target of rapamycin class of agents. Preclinical 
series have shown that everolimus exhibits 
anticancer effects in RCC and NET cell lines. A 
phase 3 placebo-controlled study in advanced 
clear-cell RCC, known as RECORD-1 (for “REnal 
Cell cancer treatment with Oral RAD001 given 
Daily”), documented that everolimus stabilizes 
tumor progression, prolongs progression-
free survival and has acceptable tolerability in 
patients previously treated with the multikinase 
inhibitors sunitinib and/or sorafenib. Everolimus 
has been granted regulatory approval for use in 




advanced RCC and incorporated into clinical 
practice guidelines, and the RECORD-1 safety 
data are being used to develop recommendations 
for managing clinically important adverse events 
in everolimus-treated patients. Ongoing clinical 
trials are evaluating everolimus as earlier RCC 
therapy (first-line for advanced disease and as 
neoadjuvant therapy), in non-clear-cell tumors, 
and in combination with various other approved 
or investigational targeted therapies for RCC. 
Regarding advanced NET, recently published 
phase 2 data support the ability of everolimus to 
improve disease control in patients with advanced 
NET as monotherapy or in combination with 
somatostatin analogue therapy, octreotide long-
acting release (LAR). Forthcoming data from 
phase 3 placebo-controlled trials of everolimus, 
one focused on monotherapy for pancreatic 
NET and the other on combination use with 
octreotide LAR for patients with advanced NET 
and a history of carcinoid syndrome, will provide 
insight into its future place in NET therapy. 
The results of a number of ongoing phase 3 
evaluations of everolimus will determine its 
broader applicability in treating breast cancer (in 
combination with chemotherapy and hormonal 
therapy), several advanced gastrointestinal 
cancers, hepatocellular carcinoma, and 
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lymphoma (in the adjuvant setting), as well as 
the various lesions associated with the tuberous 
sclerosis complex tumor suppressor gene.
Keywords: endocrine tumors; everolimus; 
gastroenteropancreatic; islet cell carcinoma; 
kidney cancer; mTOR inhibitor; neuroendocrine 
tumors; RAD001; rapamycin; renal cell 
carcinoma
INTRODUCTION
Rapamycin (also known as sirolimus), 
isolated in soil from the island of Rapa Nui 
(Easter Island) in the South Pacific in 1975,1
was initially recognized as an antifungal and 
immunosuppressive agent. Its anticancer 
properties were discovered during the 1980s, 
at a time when development of rapamycin 
was focused on the area of antirejection in 
organ transplantation recipients (resulting 
in United States and European approval for 
this use during 1999-2000). The therapeutic 
potential of rapamycin against a wide range 
of malignancies, as shown by broad activity 
in the National Cancer Institute human 
cancer cell lines,2 ultimately fueled the clinical 
development of a series of derivatives with more 
favorable pharmacologic and pharmacokinetic 
profi les; ie, temsirolimus (CCI-779), everolimus 
(RAD001), and ridaforolimus (AP23573/
MK-8669, formerly deforolimus).
Rapamycin and its derivatives comprise 
a new class of anticancer agents that block 
the mammalian target of rapamycin (mTOR) 
pathway, as shown in Figure 1. mTOR, a serine-
threonine kinase, acts as a biochemical switch, 
ensuring that supplies of energy and nutrients 
in the cell are suffi cient to maintain cell viability 
and stimulate cell growth, cell division, and 
angiogenesis. mTOR integrates the signals to 
affect multiple downstream processes, signaling 
downstream of key receptor tyrosine kinases 
such as insulin-like growth factor-1, endothelial 
growth factor, and vascular endothelial growth 
factor (VEGF) receptors, among others. Signaling 
through the phosphatidylinositol-3-kinase 
(PI3K)/Akt system stimulates its downstream 
proteins, including mTOR and ultimately 
p70S6K (the serine/threonine kinase of p70S6). 
In cancer, this aberrant activation of the mTOR 
pathway shifts cells into a trajectory favoring 
cell proliferation and survival, cell growth, 
and increased cell motility and angiogenesis, 
considered hallmarks of malignancy.3,4 The mTOR 
inhibitors are termed “downstream multisignal 
inhibitors”, differentiating this class from 
potential therapeutic agents that act upstream 
of mTOR. By blocking the mTOR pathway, the 
Akt-mediated nutrient ﬂ ux essential for cancer 
growth and the Akt-mediated antiapoptotic 
Figure 1. Growth-stimulating signals originating from 
within and outside the cell are integrated through 
mammalian target of rapamycin (mTOR) into processes 
that maintain cell viability, and stimulate cell growth, cell 
division, and angiogenesis.
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effect are inhibited, attenuating cell growth and 
slowing proliferation.5
Historically, patients with relatively 
uncommon cancers—including renal cell 
carcinoma (RCC) and neuroendocrine tumors 
(NET)—have had few therapeutic options for 
advanced disease, and in view of the limitations 
of traditional chemotherapy in these settings, 
novel molecular therapies were explored. 
This review will focus on describing clinical 
experiences to date with the oral rapamycin 
derivative everolimus in advanced RCC (a 
recently approved indication) and NET (for 
which phase 3 data are forthcoming), followed 
by an overview of ongoing and future directions 
for the development of this agent for the 
treatment of cancer.
USE OF EVEROLIMUS IN RCC
Overview of the RCC Therapeutic Landscape
RCC, arising from the cells of the proximal 
tubule, has long been regarded as one of the 
malignancies with the poorest prognosis, 
reflecting its characteristic diagnosis at an 
advanced, unresectable or metastatic stage 
and inherent resistance to chemotherapy. 
Surgery, albeit recommended across the various 
stages of RCC, is met with limited success 
particularly in advanced disease. Cytokine-based 
immunotherapy (interferon, interleukin-2) 
was regarded as standard systemic therapy for 
advanced RCC for many years6 despite producing 
modest benefit (at best) in conjunction with a 
high degree of toxicity, with average median 
survival limited to only 13 months.7 The ability 
of molecular targeted agents—including the 
VEGF receptor-tyrosine kinase inhibitors (VEGFr-
TKIs) sunitinib,8,9 sorafenib,10 and most recently 
pazopanib,11 the anti-VEGF monoclonal antibody 
bevacizumab (administered in combination 
with interferon alfa),12 and the mTOR inhibitors 
temsirolimus13 and everolimus14,15—to improve 
outcomes with relatively good tolerability 
has rapidly revolutionized the treatment of 
advanced RCC. The clinical benefit of these 
agents has been mainly in the form of disease 
stabilization and prolonged progression-
free survival (PFS). A statistically significant 
overall survival (OS) benefit was demonstrated 
with temsirolimus relative to interferon alfa 
in primary analyses.13 Secondary analyses, 
censoring for post-trial anticancer therapies or 
crossover bias, have demonstrated a significant 
OS benefit with sunitinib, with a median OS 
twice that of interferon alfa,9 sorafenib,16 and 
everolimus.15,17 Although targeted therapies 
have become the new cornerstone of systemic 
RCC therapy, eventual treatment-emergent 
resistance has emerged as a major impediment 
to long-term success with these new agents and 
is fueling research efforts to identify optimal 
sequencing and combinations.
Preclinical/Mechanistic Rationale for 
Targeting mTOR
RCC is a highly vascularized malignancy and 
therefore was identified as a compelling target 
for antiangiogenesis-based therapy. Most clear-
cell tumors, the most prominent histologic 
subtype of RCC (approximately 85% of cases), 
are associated with inactivation of the von 
Hippel-Lindau (VHL) tumor suppressor gene.18 
VHL-deficient cells are characterized by an 
upregulation of hypoxia-inducible factor (HIF) 
and a corresponding increase in VEGF and 
various other growth and angiogenic factors.18,19 
mTOR functions as a regulator of HIF and has 
been shown to be activated in clear-cell RCC,20,21 
as well as in RCC-predisposing tumor suppressor 
gene syndromes involving tuberous sclerosis 
complex 1 and 2 (TSC-1/2) and phosphatase 
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and tensin homolog (PTEN).19 Pantuck et al. 
examined expression of components of the 
mTOR pathway in samples from 375 patients 
who underwent nephrectomy for sporadic 
RCC, demonstrating particularly high mTOR 
activation among clear-cell, high-grade, and 
other poor prognosis tumors.20
Preclinically, rapamycin has demonstrated 
the ability to inhibit the cellular growth of 
RCC.21 More recently, an in vitro series found 
that everolimus significantly inhibits the growth 
of RCC cell lines and cell cycle progression 
(reducing S-phase while increasing G[0]/G[1] 
cells and altering regulatory protein expression), 
with an enhancement of antiproliferative 
and cell cycle attenuating effects when 
combined with an investigational multikinase 
inhibitor (AEE788).22
Published Clinical Trials of the Efficacy and 
Safety of Everolimus in RCC
The first published phase 2 trial of everolimus 
(dosed at 10 mg/day) for metastatic RCC, 
conducted by Amato et al., enrolled 41 patients 
with predominantly clear-cell disease who had 
received up to one prior systemic treatment.23 
Most patients (83%) had been previously 
treated, mainly in the form of immunotherapy 
(61%).23 With 57% of patients progression free 
for ≥6 months and median PFS of 11.2 months 
(95% CI: 1.7, 36.2 months), the study met the 
prespecified criteria for further evaluation.23 In 
all, 24 of 37 evaluable patients experienced some 
degree of tumor reduction.23 Objective responses 
per independent assessment were mainly stable 
disease (SD), lasting for ≥3 and ≥6 months in 
74% and 58% of patients, respectively, with 
an additional two patients achieving a partial 
response (PR).23 Considering all patients, 
median OS was 22.1 months (95% CI: 1.4, 
36.4 months).23 Most adverse events (AEs) 
were of grade 1/2 severity, with no grade 4 AEs 
reported.23 The most common treatment-related 
grade 3 AEs were pneumonitis (n=7, 18%) and 
alanine aminotransferase elevation (n=4, 10.3%), 
followed by alkaline phosphatase elevation, 
hyperglycemia, and thrombocytopenia (n=3 for 
each, 8%).23
RECORD-1 (for “REnal Cell cancer treatment 
with Oral RAD001 given Daily”) was a phase 3 
placebo-controlled trial of everolimus 10 mg/day 
in patients with metastatic RCC progressing 
after sorafenib and/or sunitinib. Prior therapy 
with cytokines and/or VEGF inhibitors 
(eg, bevacizumab) also was permitted. A 
significant PFS benefit for everolimus at the time 
of the second interim analysis prompted an early 
termination of this study.14 Based on the interim 
results derived from independent central review 
of 410 patients, everolimus was associated with 
a significant 70% improvement in PFS, with a 
median of 4.0 months versus 1.9 months with 
placebo (P<0.0001) and 6-month PFS rates of 
26% versus 2%, respectively.14 PRs were seen 
in three everolimus recipients and no placebo 
recipients, but the biggest difference was with 
respect to a near doubling of the SD rate: 63% 
with everolimus versus 32% with placebo.14 The 
nonsignificant difference in median OS between 
the two groups, not reached with everolimus 
versus 8.8 months with placebo (hazard ratio 
[HR], 0.83; 95% CI: 0.50, 1.37; P=0.23), was likely 
confounded by the high rate of crossover from 
placebo to everolimus at disease progression.14 
Two valid and independent statistical methods 
were used to calculate OS for crossover and 
estimate true survival benefit of everolimus in 
patients with metastatic RCC. Using a rank-
preserving structural failure time (RPSFT) model 
to correct the treatment effect estimate for 
crossover bias, estimated survival time was 1.9-
fold longer (95% CI: 0.5, 8.5) with everolimus 
versus placebo.15 The RPSFT approach was 
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also used to reconstruct the placebo survival 
curve resulting in a median OS for placebo of 
10.0 months.15 A second statistical analysis 
(inverse probability of censoring weights) used 
to correct for crossover demonstrated that 
everolimus reduced the risk of death by 45% 
(HR, 0.55; 95% CI: 0.31, 0.97; P=0.0389).17 
Updated efficacy based on the final data analysis 
(n=416) is consistent with the interim results, with 
median PFS of 4.9 months with everolimus and 
1.9 months with placebo (HR, 0.33; P<0.001) and 
corresponding median OS of 14.8 months and 
14.4 months (HR, 0.87; P=0.18).15 Regarding the 
final safety data for everolimus, stomatitis (44%) 
and infections (37%) were the most common 
AEs, more common than with placebo (8% and 
18%, respectively) but typically of grade 1/2 
severity.15 Grade 3/4 AEs in ≥5% of everolimus 
recipients were infections (10%), dyspnea (7%), 
and fatigue (5%).15 Noninfectious pneumonitis 
was exclusively seen in the everolimus arm, 
reported in 37 patients or 14% (n=9 grade 1; 
n=18 grade 2; n=10 grade 3).15 Laboratory 
abnormalities were also more common with 
everolimus, predominantly hemoglobin (92%) 
and lymphocyte (51%) reductions and increases 
in cholesterol (77%), triglycerides (73%), and 
glucose (57%).15 Although most were grade 1/2, 
the grade 3/4 incidences were >10% for the 
hemoglobin (13%), lymphocyte (18%), and 
glucose (15%) abnormalities.15
Using the safety data from RECORD-1, a 
multidisciplinary advisory panel has since 
developed recommendations for managing 
selected everolimus-associated AEs, as 
summarized in Table 1.24 Given the frequency 
of hyperglycemia and hyperlipidemia during 
everolimus therapy, attempts should be made 
to achieve optimal control following accepted 
practice guidelines for these conditions prior to 
initiating treatment with everolimus. Baseline 
determination and close monitoring of liver 
function tests is also warranted. In light of 
the favorable results of RECORD-1, everolimus 
was granted regulatory approval for treating 
advanced RCC in VEGFr-TKI-pretreated patients 
and has since been incorporated into the rapidly 
evolving US and European clinical practice 
guidelines (Table 2).6,25-27
Despite the availability of a growing number 
of targeted therapies with efficacy (prolongation 
of PFS and/or OS) in advanced RCC, the use of 
a single drug generally provides limited benefit, 
as the disease ultimately progresses due to the 
development of drug resistance. Resistance is 
often defined as the cause of tumor progression 
observed during ongoing therapy based on 
Response Evaluation Criteria in Solid Tumors 
(RECIST). However,  these criteria may not be 
the best indicators of resistance to targeted 
agents. Sensitivity to a targeted therapy is seen 
when tumors depend on the activity of the 
target for growth and progression.28 In theory, 
drug resistance can develop through a variety of 
tumor-related mechanisms, including genetic 
mutations that change the conformation 
or structure of a targeted protein, making it 
inaccessible to drug binding or modifying 
the interaction of the drug and its target, and 
adaptive activation of alternative signaling 
pathways. In addition, susceptibility to targeted 
therapies may vary between patients because 
of differences in drug metabolism, including 
differences in clearance rates that affect drug 
exposure, tolerability and tumor response.
To extend clinical benefit beyond that of 
a single therapy, sequential use of targeted 
therapies has become common practice. 
Although therapies directed against the same 
target often have overlapping mechanisms 
of action, it has long been thought that there 
is little cross-resistance developing against 
similar targeted therapies. A survey of seven 
cancer centers in the United States and Canada 
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conducted prior to the approval of everolimus 
as post-TKI therapy found that among patients 
with metastatic RCC who received first-line 
VEGF-targeted therapy, 34% (218/645) received 
two and 10% (70/645) received three lines 
of therapy.29 Of the 218 patients receiving 
second-line treatment, 192 received a second 
VEGF inhibitor (sunitinib, n=93; sorafenib, 
n=80; bevacizumab, n=11; or axitinib, n=8). 
This illustrates the common practice of using 
sequential therapies against the same or a similar 
target and is not surprising because until recently 
TKIs were the only therapeutic options.
Evidence supporting the sequential use 
of TKIs is limited to relatively small, mainly 
retrospective, nonrandomized analyses. In two 
such studies of patients with RCC treated with 
sorafenib followed by sunitinib or vice versa, the 
objective response rate ranged from 5% to 21% 
with SD rates from 30% to 55% with the second 
TKI.30,31 The variability in efficacy reported for 
various TKI-TKI regimens may be attributable 
at least in part to the retrospective nature and 
small size of the studies and to the differences 
in strategy employed, such as interval length 
and reason for change in therapy. To date, 
only limited data are available from controlled, 
prospective clinical studies that have compared 
the efficacy and safety of TKI-TKI sequences 
in mRCC. In a prospective phase 2 study of 
sorafenib in sunitinib-refractory patients, the 
objective response rate was 9.6%, which did 
not meet the prespecified criteria for a positive 
study.32 In a phase 2 study of sorafenib in 
patients refractory to bevacizumab or sunitinib, 
no objective responses were observed.33
The results of RECORD-1 demonstrate the 
effectiveness of one sequential approach in 
patients with mRCC in a well-designed and well-
executed prospective randomized trial. Patients 
who experienced disease progression on or after 
first-line therapy with a VEGF receptor inhibitor 
(sunitinib or sorafenib) received significant 
clinical benefits from everolimus as second-
line therapy.14 Based on this level I evidence, 
everolimus has been incorporated into US and 
European treatment guidelines for RCC with a 
category 1/grade A recommendation.6, 25-27
To further determine the optimum sequence 
for using sunitinib and everolimus, the RECORD-3 
study, a prospective open-label phase 2 crossover 
study to compare the efficacy and safety of 
everolimus as first-line therapy followed by 
second-line sunitinib versus sunitinib as first-
line followed by second-line everolimus has 
been initiated.  Ultimately, optimal treatment 
sequences may need to be patient specific, 
taking into account comorbid conditions and, if 
possible, genotypic characteristics.
Ongoing Clinical Trials of Everolimus in RCC
Everolimus monotherapy is being evaluated 
further for advanced RCC (Table 3), specifically 
in patients with the less common non-clear-
cell subtypes (including the phase 2 RAPTOR 
study of everolimus in advanced papillary RCC 
[NCT00688753]), in the neoadjuvant setting, 
and in sequence with sunitinib. As noted above, 
in order to determine the optimal sequencing 
of VEGFr-TKIs and mTOR inhibitors (mTOR 
inhibitor to TKI or TKI to mTOR inhibitor), 
the RECORD-3 phase 2 crossover study is 
randomizing patients with previously untreated 
metastatic RCC to receive either first-line 
everolimus followed by sunitinib at time of 
progressive disease (PD) or first-line sunitinib 
followed by everolimus upon PD, with PFS as 
the primary endpoint (NCT00903175). Overall, 
the majority of everolimus studies that have 
completed or continue enrolling patients with 
RCC are investigating dual agent targeted 
combinations.  For example, three separate 
phase 2 trials are evaluating the combination 
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of everolimus plus bevacizumab, including 
the RECORD-2 evaluation of everolimus plus 
bevacizumab versus interferon alfa 2a plus 
bevacizumab as first-line treatment of metastatic 
RCC of clear-cell histology (NCT00719264).
USE OF EVEROLIMUS IN 
ADVANCED NET
Overview of the NET Therapeutic Landscape
NET are relatively rare heterogeneous 
malignancies thought to originate from 
neuroendocrine cells scattered throughout 
the gastrointestinal tract, bronchopulmonary 
tree, and in various other locations. NET 
are often metastatic and incurable when 
diagnosed, and most patients succumb to 
the disease. An analysis of the Surveillance, 
Epidemiology, and End Results (SEER) Program 
registries from 1973 to 2004 determined that 
median OS in patients with well or moderately 
differentiated NET with distant metastasis 
was 33 months.34 Surgery represents the only 
curative option but is suitable only for patients 
with localized and limited disease. For patients 
with well and moderately differentiated 
metastatic NET, treatment decisions have 
been historically based on the severity of 
symptoms (stemming from the production 
of bioactive amines and peptides and/or 
anatomic location of the tumor), performance 
status, and the extent of disease burden and 
progression.4 In the past, patients who were 
relatively asymptomatic or who had slow 
tumor growth were treated conservatively; 
Table 3. Ongoing trials in RCC and NET.*
Phase 1 Phase 1/2 Phase 2 Phase 3




Everolimus + vatalanib 
(various advanced solid 
tumors, including RCC)
Monotherapy: non-clear-cell 
subtypes (multiple trials, 
including RAPTOR)
Monotherapy: neoadjuvant
Monotherapy: vs sunitinib, 
first-line and second-line 
(RECORD-3)
Everolimus + bevacizumab 
(multiple trials, including 
RECORD-2)
Everolimus + imatinib 
mesylate 
None ongoing
NET Everolimus + sorafenib
Everolimus + vatalanib 
(various advanced 
solid tumors, including 
pancreatic NET)
Everolimus + pasireotide 
Everolimus + temozolomide Monotherapy: first-




Everolimus + octreotide 
depot vs octreotide depot 
alone in advanced carcinoids 
(RADIANT-2)
Everolimus vs placebo in 
advanced pancreatic NET 
(RADIANT-3)
*Completed accrual (but study ongoing) or active recruitment, per http://clinicaltrials.gov as of February 28, 2010.
NET=neuroendocrine tumors; RCC=renal cell carcinoma.
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however, the treatment paradigm has recently 
shifted with a greater emphasis on disease 
control. Somatostatin analogs (SAs) are highly 
effective in symptomatic control of syndromes 
associated with functional NET and improving 
quality of life, with recent evidence from the 
PROMID study supporting true cytostatic 
potential for octreotide long-acting release 
(LAR), at least for patients with small intestine 
(midgut) NET.35 Benefit from octreotide LAR 
was observed in patients with and without 
symptoms of carcinoid syndrome.35 Individual 
patients may derive benefit from other 
systemic modalities, such as interferons (for 
slow-growing intestinal tumors) or cytotoxic 
chemotherapy (particularly for pancreatic 
NET), but objective responses and long-term 
benefits are rare. Radionuclide therapy, with 
either 131I-MIBG or a radiolabeled (90Y or 177Lu) 
SA, has shown promising results, but long-term 
prospective studies are lacking and it remains 
of limited availability.
Preclinical/Mechanistic Rationale for 
Targeting mTOR
The rationale for mTOR-targeted therapy 
for the treatment of advanced NET is based 
on increased expression/activation of mTOR 
pathway components and drug efficacy in 
animal models and cell lines and human 
tumors.36 Expression profiling analyses identified 
downregulated expression of TSC-2 and PTEN, 
key inhibitors of the mTOR pathway, in both 
functioning and nonfunctioning pancreatic NET, 
and demonstrated that low expression of TSC-2 
or PTEN was associated with a worse prognosis.37 
Moreover, certain genetic syndromes associated 
with the development of low-grade NET have 
been found to be related to aberrations of the 
mTOR pathway; for example, the mutation 
of TSC-1/2 gene in tuberous sclerosis, NF-1 in 
neurofibromatosis, or the VHL gene in VHL 
disease have been implicated in mTOR activation 
and the development of NET.38,39
The antiproliferative effect of everolimus 
inhibition on the mTOR pathway has been 
demonstrated in neuroendocrine cell lines. For 
example, Zitzmann et al. demonstrated potent 
dose-dependent inhibition for everolimus 
on BON human pancreatic NET cells, 
inducing apoptosis and cell growth arrest.40 
In a subsequent report describing the mode 
of action of octreotide and everolimus on the 
rodent-derived insulin-secreting cell line,3 
both treatments were shown to inhibit the 
phosphorylation of p70S6K at a site downstream 
of the serine-threonine kinase Akt and attenuate 
proliferation. Sensitivity of cells to rapamycin 
and its derivatives may be limited by a negative 
feedback loop resulting in increased Akt/mTOR 
signaling. The addition of octreotide has been 
shown to sensitize tumor cells to rapamycin 
treatment by inhibiting Akt activation and 
increasing the antiproliferative effect of 
rapamycin in tumor cells.41 The inhibitory 
action of everolimus on cell proliferation and 
Akt/mTOR/p70S6K pathway activation has been 
demonstrated in a human medullary thyroid 
carcinoma (MTC) cell line (TT) and cultured 
human MTCs.42 Everolimus significantly 
inhibited the cell viability of both TT cells and 
MTC primary culture cells in a dose-dependent 
and time-dependent fashion. It inhibited the 
phosphorylation of Akt downstream targets, 
mTOR-Ser2448 and p70S6K-Thr389, while Akt 
phosphorylation was not affected. Moreover, 
everolimus induced cell cycle arrest in the 
G(0)/G(1) phase in TT cells but exerted no effect 
on cell apoptosis. Overall, the in vitro effects of 
everolimus on NET cells in these published series 
and other unpublished experience (available in 
abstract form)43,44 collectively support its clinical 
evaluation in NET.
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Published Clinical Trials of the Efficacy and 
Safety of Everolimus in NET
In 2008, the first phase 2 trial of everolimus 
in patients with low-grade to intermediate-grade 
NET was published by Yao et al.45 The study 
enrolled 60 patients with advanced, low-grade to 
intermediate-grade NET (30 pancreatic NET and 
30 lung NET or gastrointestinal NET [carcinoid]). 
Patients received daily everolimus 5 mg (n=30) 
or 10 mg (n=30) orally in combination with 
octreotide LAR (30 mg intramuscularly every 
4 weeks). Efficacy was determined by RECIST 
criteria. The overall response rate was 20% per 
intention-to-treat analysis and 23% in the per-
protocol population, in which 13 patients (22%) 
achieved a PR, 42 (70%) maintained SD, and five 
(22%) had disease progression. PRs were more 
frequent in patients with pancreatic NET than 
in patients with nonpancreatic NET (27% versus 
17%). Regarding the different dosages, everolimus 
10 mg produced a higher PR rate than 5 mg 
(30% versus 13%). Median PFS was 60 weeks 
overall, longer in patients with nonpancreatic 
NET (63 weeks) than in patients with pancreatic 
NET (50 weeks). With regard to tumor shrinkage, 
the majority of patients showed some degree of 
tumor reduction by “waterfall” plot. Treatment 
was generally well tolerated; the most common 
grade 3/4 AEs were hypophosphatemia (11%), 
fatigue (11%), diarrhea (11%), hyperglycemia 
(9%), and aphthous ulcers (8%).45 Four patients 
treated at the 10-mg level developed grade 2 
(n=3) or grade 3 (n=1) pneumonitis, supportively 
managed with treatment interruption and 
steroids (and dose reduction to 5 mg for the 
grade 3 case).45 The study demonstrated that 
everolimus was effective and well tolerated in 
the treatment of low-grade to intermediate-
grade NET.
More recently, Yao et al. published the results 
of an open-label phase 2 study of everolimus 
in patients with metastatic pancreatic NET 
after failure of chemotherapy.46 In this much 
larger study, known as RADIANT-1 (RAD001 
In Advanced Neuroendocrine Tumors), 
160 patients were recruited from 36 centers 
in 11 countries between June 2006 and 
June 2007. All participants had confirmed 
well to moderately differentiated, advanced 
(unresectable or metastatic) pancreatic 
NET with RECIST-documented PD during 
or after chemotherapy. They were divided 
into two strata by prior octreotide therapy. 
Patients who had not received octreotide 
were assigned to stratum 1 (everolimus 
10 mg/day, n=115), while those who were on 
octreotide LAR for ≥3 consecutive months 
at study entry were assigned to stratum 2 
(everolimus 10 mg/day plus octreotide 
LAR 30 mg intramuscularly every 4 weeks, 
n=45). Efficacy was determined by RECIST at 
baseline and every 3 months, the biomarkers 
chromogranin A (CgA) and neuron-specific 
enolase (NSE) were evaluated at baseline and 
monthly if elevated at baseline,46 and all 
radiologic images were reviewed by central 
radiology and investigator assessment. The 
overall response rate by central radiology was 
9.6% (11/115) in stratum 1 and 4.4% (2/45) 
in stratum 2. In stratum 1, SD was noted in 
78 patients (68%) while 16 patients (14%) 
had PD. In stratum 2, 36 patients (80%) had 
SD and no patient had PD. Efficacy data from 
both strata were more striking considering 
that patients in this study had PD upon 
study entry. Median duration of response 
by central radiology was 10.6 months in 
stratum 1 but was not calculated in stratum 2 
given the small number of patients. Median 
PFS was 9.7 months and 16.7 months in 
strata 1 and 2, respectively. Median OS in 
stratum 1 was 24.9 months; however, OS had 
not been reached for stratum 2 at the time of 
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data cutoff. The 24-month survival rate was 
similar in both strata (51% stratum 1; 55% 
stratum 2). An early CgA response (defined as 
normalization or ≥30% decrease by week 4) 
was seen in 47% (33/71) of patients in 
stratum 1 and 59% (13/22) in stratum 2, with 
early NSE response rates of 72% (28/39) and 
50% (5/10), respectively.46 The early biomarker 
responders also had significantly longer 
median PFS. Median PFS was 13.3 months in 
early CgA responders versus 7.5 months in 
nonearly CgA responders of stratum 1, while 
median PFS in early NSE responders was 
8.6 months versus 2.9 months in nonearly 
responders in stratum 1. PFS by CgA or NSE 
in stratum 2 were not evaluated because of 
the small number of patients.
AEs were generally mild and tolerable, the 
most common being stomatitis, rash, diarrhea, 
fatigue, and nausea. The most frequent 
grade 3/4 AEs were asthenia in stratum 1 
(5%) and thrombocytopenia in stratum 2 
(9%).46 Grade 1/2 pneumonitis was reported 
in both strata (n=7 and n=6 in strata 1 and 
2, respectively), which was reversible by 
dosage interruption and modification for the 
symptomatic grade 2 cases.46 Evaluation of the 
pharmacokinetic effects of coadministration 
of octreotide LAR and everolimus showed 
that neither everolimus nor octreotide affect 
exposure to the other drug. This trial showed 
promising results in that everolimus, both 
alone and combined with octreotide LAR, 
was an effective treatment for advanced 
pancreatic NET after fai lure of prior 
systemic chemotherapy.
Ongoing Clinical Trials of Everolimus in NET
Clinical trials of everolimus are ongoing 
across different types of NET (Table 3). 
Two placebo-controlled phase 3 trials are 
underway within the RADIANT series, 
investigating everolimus plus octreotide 
LAR versus octreotide LAR alone in patients 
with advanced carcinoids (RADIANT-2, 
NCT00412061) and everolimus monotherapy 
for advanced pancreatic NET (RADIANT-3, 
NCT00363051).4,36,46 These are the largest 
randomized controlled trials to be undertaken 
in this disease setting and are fully enrolled 
with over 800 patients. Additionally, an open-
label phase 2 study in multiple European 
centers (RAMSETE, NCT00688623) is exploring 
everolimus as monotherapy for the first-line 
treatment of patients with nonfunctioning 
gastroenteropancreatic NET lacking carcinoid 
syndrome symptoms.36 Additionally, phase 1 
and 2 trial designs are combining everolimus 
with chemotherapy (temozolomide), other 
targeted agents (bevacizumab, erlotinib, 
sorafenib, vatalanib), and the investigational 
SA pasireotide.
NET Case Reports of Interest
mTOR Inhibition in the Glycemic Control of 
Insulinoma
There have been two published case studies 
on the use of rapamycin and everolimus to 
control intractable hypoglycemia in patients 
with insulinoma.47,48 Kulke et al. demonstrated 
the normalization of serum glucose levels after 
everolimus.47 The four patients in their series 
required depot octreotide, diazoxide, and 
glucose supplementation for glucose control 
before commencing everolimus: two achieved 
PRs while the remaining two had SD after 
everolimus. All had substantial improvement 
in glycemic control after receiving everolimus, 
thereby allowing successful discontinuation 
of diazoxide and glucose supplements. 
One patient with tumor regression had 
recurrent hypoglycemia after stopping 
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everolimus. The proposed mechanisms for 
these very encouraging results were tumor 
regression plus a direct effect on glycemic 
control. The latter mechanism is supported 
by preclinical studies which demonstrate 
that mTOR inhibition in pancreatic beta 
cells directly modulates insulin production 
and release.49,50 Consistent with a role of 
mTOR in glycemic control, hyperglycemia 
is a common AE in patients treated with 
everolimus.15,46  A similar effect of rapamycin 
on treatment of intractable hypoglycemia 
in insulinoma has been observed.48 An older 
patient with metastatic insulinoma had 
refractory hypoglycemia while receiving 
diazoxide, hydrochlorothiazide, octreotide, 
phenytoin, and dextrose infusion. After 
starting rapamycin 2 mg/day, glycemic 
control was maintained solely on rapamycin 
and hydrochlorothiazide. Interestingly, 
insulin/glucose ratio showed a steady increase 
indicating that rapamycin and its derivative 
everolimus may exert its hyperglycemic effects 
via increasing peripheral insulin resistance.
Institutional Experience in Malignant 
Pheochromocytomas and Paragangliomas
Pheochromocytomas/paragangliomas are 
NET characteristically resistant to conventional 
treatment modalities. To date, we have treated 
four such patients presenting with progressive, 
metastatic disease after prior treatment with 
different forms of surgery, chemotherapy, and 
radionuclide therapy.51 All four were treated 
with everolimus 10 mg/day with or without 
concomitant chemotherapy (temozolomide 
and dacarbazine) for 3-6 months until 
documentation of PD or death.51 The results 
were relatively disappointing, with all patients 
showing radiological evidence of PD; three 
died of PD, although one survived >1 year after 
everolimus discontinuation. Everolimus was 
generally well tolerated, although one patient 
developed pneumonitis that subsequently 
improved with conservative treatment. Despite 
the experience described here, the lack of any 
treatment with established efficacy for malignant 
pheochromocytomas supports multicenter and 
Table 4. Ongoing phase 3 trials beyond RCC and NET.*
Tumor type Phase 3 studies
Breast cancer Neoadjuvant with paclitaxel (GeparQuinto)
HER2-positive locally advanced or metastatic (with paclitaxel and trastuzumab [BOLERO-1] 
or vinorelbine and trastuzumab [BOLERO-3])
With exemestane in estrogen receptor-positive locally advanced or metastatic refractory to 
letrozole or anastrozole (BOLERO-2)
Gastrointestinal Advanced gastric carcinoma (GRANITE-1)
Imatinib-resistant gastrointestinal stromal tumors 
Liver Advanced hepatocellular carcinoma (EVOLVE-1)
Lymphoma Adjuvant therapy after first-line rituximab chemotherapy in poor-risk diffuse large B-cell 
lymphoma (PILLAR-2)
TSC-associated conditions TSC-associated subependymal giant cell astrocytoma (EXIST-1)
TSC-associated or sporadic lymphangioleiomyomatosis-associated angiomyolipoma (EXIST-2) 
*Completed accrual (but study ongoing) or active or pending recruitment, per http://clinicaltrials.gov as of February 28, 
2010.
NET=neuroendocrine tumors; RCC=renal cell carcinoma; TSC=tuberous sclerosis complex.
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multinational investigations of this new novel 
therapy, ideally in combination with additional 
forms of treatment.
ADDITIONAL PHASE 3 
EVEROLIMUS STUDIES AND 
FUTURE DIRECTIONS
As summarized in Table 4, numerous phase 3 
clinical trials of everolimus are ongoing in tumor 
types beyond RCC and NET, including those 
studying combination use with chemotherapy or 
hormonal therapy for breast cancer, monotherapy 
for various advanced gastrointestinal and liver 
malignancies, and adjuvant use for poor-risk 
diffuse large B-cell lymphoma. Additional 
phase 3 evaluations of everolimus monotherapy 
are underway in populations with tuberous 
sclerosis complex (TSC)-associated subependymal 




In this review we have described the 
mechanism, efficacy, and safety of everolimus 
in advanced RCC and various types of advanced 
NET. Although everolimus does not represent the 
much needed cure for these rare malignancies, 
it is undoubtedly effective in improving disease 
control. The demonstrated benefit of everolimus 
in VEGFr-TKI-pretreated metastatic RCC has filled 
a major unmet need, and new questions regarding 
the optimal sequences and combinations of 
targeted agents are being addressed in ongoing 
clinical trials. In addition to reducing the 
tumor size and controlling disease progression 
in NET (with or without SA coadministration), 
emerging evidence suggests that everolimus 
may improve symptomatic hypoglycemia 
in malignant insulinomas. Everolimus has 
displayed an acceptable tolerability profile in 
clinical trials, with associated AEs mostly of 
grade 1/2 severity and generally manageable. 
The results of ongoing phase 3 trials will provide 
further insight into the role of everolimus as 
part of combination therapies and as a front-
line regimen in the treatment of advanced 
RCC and NET; additionally, everolimus is being 
investigated in a number of other solid tumors 
and hematologic malignancies.
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